Mesoblast (MESO) Change in Account Payables (2017 - 2025)
Mesoblast's (MESO) quarterly Change in Account Payables came in at $4.7 million in Q2 2025, up 149.58% year-on-year from $1.9 million in Q2 2024, and up 149.58% quarter-over-quarter from -$9.5 million in Q2 2024.
Mesoblast (MESO) Change in Account Payables (2017 - 2025) Analysis & Trends
Mesoblast has disclosed Change in Account Payables across 9 years of filings, most recently posting $4.7 million for Q2 2025.
- Change in Account Payables for Q2 2025 came in at $4.7 million, up 149.58% year-over-year; the trailing twelve-month figure through Jun 2025 was -$11.7 million (up 36.49% YoY), and the FY2025 annual result was $4.7 million, up 149.58% from the prior year.
- Change in Account Payables came in at $4.7 million for Q2 2025 at Mesoblast, up from -$9.5 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $5.1 million in Q4 2021 to a low of -$9.5 million in Q4 2023.
- The 5-year median for Change in Account Payables is -$529000.0 (2021), against an average of -$827153.8.
- Across the five-year window, Change in Account Payables surged 1346.12% in 2021 and sank 464.26% in 2024, its largest moves.
- Mesoblast's Change in Account Payables stood at $5.1 million in 2021, then slipped by 2.69% to $5.0 million in 2022, then tumbled by 290.15% to -$9.5 million in 2023, then changed by 0.0% to -$9.5 million in 2024, then jumped by 149.58% to $4.7 million in 2025.
- The last three Change in Account Payables figures came in at $4.7 million (Q2 2025), -$9.5 million (Q2 2024), and -$9.5 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 4.71 Mn |
| Jun 30, 2025 | 4.71 Mn |
| Jun 30, 2024 | -9.50 Mn |
| Jun 30, 2024 | -9.50 Mn |
| Dec 31, 2023 | -9.50 Mn |
| Dec 31, 2023 | -9.50 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Mar 31, 2023 | -2.00 Mn |
| Mar 31, 2023 | -2.00 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Sep 30, 2022 | -2.39 Mn |
| Sep 30, 2022 | -2.39 Mn |
| Jun 30, 2022 | 691,000.00 |
| Jun 30, 2022 | 691,000.00 |
| Mar 31, 2022 | -1.43 Mn |
| Mar 31, 2022 | -1.43 Mn |
| Dec 31, 2021 | 5.13 Mn |
| Dec 31, 2021 | 5.13 Mn |